About

Fred Dom is one of the original founders and Chief Executive Officer of HiFiBiO Therapeutics. He is a serial entrepreneur with expertise in private capital investment and biotech formation in the Netherlands, France, and US. Fred holds board positions in Calyxia (France), Kapsera (France) and Oncode Accelerator (Dutch public-private initiative with €325 million funding from National Growth Fund), and he is a member of the Advisory Board of Dutch Life Science and Health industry.

Previously, Fred was Chief Executive Officer and co-founder of Saber Bio (created in 2021), which was acquired by a world leading life science tools company in 2024. Before Saber, Fred held CEO and CFO positions at HiFiBiO Therapeutics.

Fred holds a B.Sc. and M.Sc. in economics from the Erasmus University in Rotterdam, the Netherlands.

Jinping is the Senior Vice President, Head of Research and Development at HiFiBiO Therapeutics. Jinping has more than 25 years of experience in drug discovery and development.

Prior to HiFiBiO, Jinping was at Bristol-Myers Squibb working on preclinical optimization and nonclinical characterization of diverse NCEs in oncology, immunology, CV, and fibrotic diseases, contributing to the development and approval of ixabepilone and apixaban. 

Jinping received his B.S. from University of Science & Technology of China and his Ph.D. in Biological Chemistry from MIT.

Roshan Kumar is the Head of Translational Medicine at HiFiBiO Therapeutics. He is a scientist with over 20 years of experience in the study of complex biological systems, with a focus on human immunology and immune-mediated disease. Roshan has been with HiFiBiO for more than a decade, where he has helped develop and apply the company’s single-cell and immune profiling platform to discover and advance a pipeline of immunomodulatory antibodies for autoimmune diseases and cancer. Roshan has also led HiFiBiO’s External Innovation where he has been responsible for the discovery and development of over 10 novel biotherapeutics under collaborations with MNCs. His current focus is on translating human immune biology into biomarker-driven insights that inform therapeutic strategy and early clinical development.

Roshan received a B.S. from the California Institute of Technology and Ph.D. in Biochemistry from the Scripps Research Institute. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Melissa Harney is the Head of Clinical Operations & Regulatory Affairs at HiFiBiO Therapeutics, where she leads global clinical execution and regulatory strategy across the company’s Immunology & Inflammation and Immuno-Oncology programs. She brings over 20 years of experience in clinical development, regulatory oversight, and global trial operations within the biotech and pharmaceutical sectors.

Prior to joining HiFiBiO, Melissa held senior clinical operations leadership roles at Seven and Eight Biopharmaceuticals and supported global development programs at Advaxis, Daiichi Sankyo, and Pearl Therapeutics (acquired by AstraZeneca). She has overseen clinical and regulatory activities supporting both in-licensing and out-licensing transactions, including programs advanced through strategic partnerships with Eikon Therapeutics and AstraZeneca.

Melissa holds a Bachelor of Science degree in Clinical Psychology and an Associate degree in Healthcare Science, and completed professional certification programs through Association of Clinical Research Professionals (ACRP).

Yun-Yueh Lu is the Head of Research, Head of China Operations at HiFiBiO Therapeutics. She is a biologist with 10 years of biopharma industry experience. She currently oversees all aspects of preclinical research activities, along with managing general operational responsibilities in China.

Prior to joining HiFiBiO Therapeutics, she was part of the team at Sanofi, where she contributed to the discovery of small molecule therapies targeting viral diseases.

Yun-Yueh holds a Ph.D. in Infection Biology from Basel University in Switzerland, a M.Sc. in Virology from Wageningen University in the Netherland, and a B.Sc . from National Chung-Hsing University in Taiwan.

Alexandre Grassin is Senior Vice President, Head of Finance at HiFiBiO Therapeutics. He is a seasoned biotech finance executive with over 25 years of international experience across the U.S. and Europe, spanning both private and public companies.

Alex has supported multiple equity and debt financings and played a central role in bringing companies to the public markets on Euronext and Nasdaq through reverse takeovers (RTO) and SPAC transactions, as well as in M&A exits. At HiFiBiO, he oversees global finance and accounting and works closely with the executive team to support strategic planning, financial discipline, and long-term value creation.

Prior to HiFiBiO, Alex served as CFO or interim CFO for several biotech and medtech companies, including Genkyotex, Aleva Neurotherapeutics, and enGene, and held senior finance roles at Alexion and Novartis. He began his career at KPMG in audit.

Alex holds a degree in International Management and is based in Boston.

Tim Miller is Head of Business Development at HiFiBiO Therapeutics, where he leads global partnering strategy to advance the company’s biotherapeutic pipeline. He brings more than a decade of experience spanning business development, alliance management, and contracting within the life sciences and biotechnology sectors.

Prior to HiFiBiO, Tim served as Director of Business Development at MindWalk (formerly IPA), where he led global licensing and strategic partnerships across five international operating sites. In parallel, he oversaw the company’s global contracting and  Prior to MindWalk, Tim worked at Harbour BioMed, where he focused on technology licensing and alliance management, with particular emphasis on the company’s proprietary transgenic animal platforms supporting antibody discovery and therapeutic development.

Tim holds a Master’s degree in International Infectious Disease Management and Biosecurity and a Bachelor’s degree in Microbiology, both from North Dakota State University.